compounding pharmacies
Coverage of compounding pharmacies in the Nexus archive.
- FDA panel votes to add peptides to permitted list despite opposition from agency scientists
The FDA's committee on compounded drugs voted to add peptides to the list of substances compounding pharmacies can make, despite opposition from agency scientists who raised concerns about the lack of demonstrated benefits.
- STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
An FDA advisory panel will discuss allowing compounding pharmacies to manufacture seven peptides currently deemed unsafe. The panel includes members with potential conflicts of interest, such as physicians who prescribe peptides and Tennessee state Sen. Bobby Harshbarger, whose mother, U.S. Rep. Diana Harshbarger, advocates for looser peptide regulations.
- FDA reviews peptide injections favored by RFK Jr. and wellness influencers
The FDA is reviewing peptides, unproven substances popularized by RFK Jr. and wellness influencers, with health advisers divided over their safety and efficacy. The meeting includes experts with financial ties to the peptide industry, raising concerns about conflicts of interest.
- What's behind the push to make peptide therapies more readily available
Peptide therapies, marketed for longevity and wellness benefits, are sold through a grey market online. Compounding pharmacies argue they should be allowed to produce these unproven therapies legally to meet demand.
- What's behind the push to make peptide therapies more readily available
Peptide therapies, marketed for longevity and wellness, are sold through an online grey market despite lacking proven efficacy. Compounding pharmacies argue they should be legally permitted to produce these therapies to meet demand.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA will convene a panel to review the safety of popular peptide injections, with participants including doctors and pharmacists financially tied to the peptide industry. The meeting, part of efforts to reshape health policy under Robert F. Kennedy Jr., will assess peptides like BPC-157 and TB-500, which the FDA has previously warned are unapproved and risky.
- STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
The FDA announced eight new panelists to advise on regulations for compounding pharmacies manufacturing peptides. Most panelists are linked to businesses promoting peptides, and one, Bobby Harshbarger, is a pharmacist and Tennessee state senator. A professor raised concerns about the panelists' ties to unproven peptide and stem cell treatments.
- ‘Wild West’ peptide craze surges beyond GLP-1s as FDA faces pressure to ease access
The peptide market is experiencing rapid growth as GLP-1 weight-loss medications gain popularity, with largely unregulated peptides being sold through compounding pharmacies and unverified vendors. The FDA is evaluating whether to loosen regulations on several peptides, while compounding pharmacies have expanded to meet demand and offer dosing flexibility that commercial products cannot provide.